BioNTech SE (NASDAQ:BNTX) Receives $142.72 Average Price Target from Brokerages

BioNTech SE (NASDAQ:BNTX) has been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $142.72.

A number of equities research analysts have commented on BNTX shares. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. HC Wainwright restated a “buy” rating and issued a $150.00 price target on shares of BioNTech in a report on Monday, November 18th. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target for the company. Finally, Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th.

BioNTech Trading Down 1.8 %

BNTX opened at $115.17 on Thursday. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $115.04 and a 200-day moving average of $105.32. The stock has a market cap of $27.61 billion, a PE ratio of -54.84 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the company posted $0.73 earnings per share. BioNTech’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, sell-side analysts predict that BioNTech will post -3.77 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Fred Alger Management LLC bought a new position in shares of BioNTech during the third quarter valued at about $59,485,000. Baillie Gifford & Co. lifted its position in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after purchasing an additional 7,340 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of BioNTech by 123.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after purchasing an additional 74,119 shares in the last quarter. Finally, Discovery Capital Management LLC CT bought a new stake in BioNTech in the second quarter worth about $2,467,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.